Balaji Amines Limited — PPTs, 06-06-2025: Investor Presentation

1. Financial Highlights:

Consolidated revenue declined 14% YoY to ₹1,430 Cr, with Q4 revenue up 12% QoQ at ₹361 Cr. EBITDA fell 25% YoY to ₹265 Cr for FY25, and PAT dropped 31% YoY to ₹159 Cr. Q4 EBITDA improved to ₹68 Cr (19% margin), and PAT rose to ₹40 Cr. Standalone revenue declined 5% YoY to ₹1,296 Cr; EBITDA decreased 7% to ₹249 Cr, and PAT was down 9% at ₹156 Cr. Margin contraction reflects cost pressures, though Q4 showed signs of recovery. The balance sheet remains solid, with net worth of ₹1,839 Cr and controlled debt of ~₹120 Cr, supporting ongoing capex. Operating cash flows remain healthy.

2. Strategic Initiatives & Growth Drivers:

Capex plans include commissioning an 8MW solar power plant to reduce energy costs and capacity expansions for Electronic Grade DMC, Pharma Grade Propylene Glycol, Dimethyl Ether, N-Methyl Morpholine, and Iso Propyl Amine. Methylamines capacity nearly doubled to 88,000 TPA, targeting pharma and agrochemical growth. Greenfield projects with ₹750 Cr capex at Balaji Specialty Chemicals are underway for producing Hydrogen Cyanide, Sodium Cyanide, EDTA, and other value-added chemicals, slated by FY26-27. Focus on indigenous technology reduces costs and boosts competitiveness.

3. Business Developments:

New product lines include electronic grade DMC, pharma-grade Propylene Glycol, and a forthcoming Dimethyl Ether plant (commissioning FY26). Modifications to produce Iso Propyl Amines are progressing, pending approvals. Acrylonitrile plant upgrades continue. Subsidiary Balaji Specialty Chemicals is advancing greenfield and brownfield projects, supporting specialty chemicals portfolio expansion and exports to Europe, US, and China. Solar integration supports ESG commitments.

4. Market Position & Competitive Advantage:

Balaji Amines is India’s largest aliphatic amines maker with a diversified portfolio of 40+ products and forward integration into specialty chemicals. It leverages indigenous technology, robust quality certifications (ISO, REACH, WHO-GMP), and zero liquid discharge processes. The industry’s oligopolistic nature, high entry barriers, and strategic plant locations restrict competition and imports. Strong foothold in pharma and agro sectors enhances pricing power and margin stability.

5. Investor Implications:

Margin and profit pressures from cost inflation persist, but capacity expansions, product diversification, and vertical integration point to positive growth potential in pharma, agro, and specialty chemicals. Capex funded through internal accruals reflects disciplined financials. Execution risk relates to commissioning schedules and market recovery. ESG focus and strong cash flows support sustainable medium-term value creation. Investors should track margin trends and operational leverage as new capacities ramp up.